Boston Scientific (NYSE:BSX) Upgraded at Oppenheimer

Key Points

• Boston Scientific's stock was upgraded by Oppenheimer from a "market perform" rating to an "outperform" rating, with a price target set at $125.00, indicating a potential upside of 16.67%.
• The company reported a quarterly earnings per share (EPS) of $0.75, exceeding analysts' expectations and demonstrating a revenue increase of 22.8% year-over-year.
• Institutional investors own 89.07% of Boston Scientific's stock, reflecting strong interest from larger investment firms.

Boston Scientific (NYSE:BSX - Get Free Report) was upgraded by stock analysts at Oppenheimer from a "market perform" rating to an "outperform" rating in a report issued on Monday,Finviz reports. The firm currently has a $125.00 price target on the medical equipment provider's stock. Oppenheimer's price target points to a potential upside of 16.67% from the stock's previous close.

Other equities analysts also recently issued research reports about the stock. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Wells Fargo & Company lifted their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Barclays lifted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Morgan Stanley lifted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Finally, Citigroup reaffirmed a "buy" rating and set a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $117.79.

Boston Scientific Stock Performance

BSX opened at $107.14 on Monday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market cap of $158.76 billion, a price-to-earnings ratio of 63.78, a PEG ratio of 2.58 and a beta of 0.65. The company's 50 day moving average is $104.77 and its 200 day moving average is $102.15. Boston Scientific has a 12-month low of $80.64 and a 12-month high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm's revenue was up 22.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts predict that Boston Scientific will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Boston Scientific by 1.9% in the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider's stock worth $14,729,575,000 after purchasing an additional 2,545,381 shares during the last quarter. State Street Corp increased its position in Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider's stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the last quarter. Geode Capital Management LLC increased its position in Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider's stock worth $3,466,320,000 after purchasing an additional 622,602 shares during the last quarter. Norges Bank bought a new stake in Boston Scientific in the second quarter worth $2,089,937,000. Finally, Invesco Ltd. boosted its stake in Boston Scientific by 1.4% during the second quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider's stock worth $1,810,022,000 after buying an additional 226,578 shares during the period. Institutional investors own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.